89bio Inc Stock Working Capital
| ETNB Stock | USD 8.99 0.15 1.64% |
89bio Inc fundamentals help investors to digest information that contributes to 89bio's financial success or failures. It also enables traders to predict the movement of 89bio Stock. The fundamental analysis module provides a way to measure 89bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to 89bio stock.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | 563.9 M | 592.1 M | |
| Change In Working Capital | 657 K | 624.1 K |
89bio | Working Capital |
89bio Inc Company Working Capital Analysis
89bio's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current 89bio Working Capital | 563.92 M |
Most of 89bio's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, 89bio Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
89bio Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for 89bio is extremely important. It helps to project a fair market value of 89bio Stock properly, considering its historical fundamentals such as Working Capital. Since 89bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of 89bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of 89bio's interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
89bio Capital Surpluse
Capital Surpluse |
|
According to the company's disclosures, 89bio Inc has a Working Capital of 563.92 M. This is 32.48% higher than that of the Biotechnology sector and 4.7% higher than that of the Health Care industry. The working capital for all United States stocks is 61.85% higher than that of the company.
89bio Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses 89bio's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of 89bio could also be used in its relative valuation, which is a method of valuing 89bio by comparing valuation metrics of similar companies.89bio is currently under evaluation in working capital category among its peers.
89bio Current Valuation Drivers
We derive many important indicators used in calculating different scores of 89bio from analyzing 89bio's financial statements. These drivers represent accounts that assess 89bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of 89bio's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 279.7M | 392.1M | 262.7M | 443.1M | 398.8M | 235.7M | |
| Enterprise Value | 186.3M | 187.4M | 131.3M | 407.9M | 367.1M | 385.4M |
89bio ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, 89bio's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to 89bio's managers, analysts, and investors.Environmental | Governance | Social |
89bio Fundamentals
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | 670.86 M | ||||
| Shares Outstanding | 117.58 M | ||||
| Shares Owned By Insiders | 0.58 % | ||||
| Shares Owned By Institutions | 93.84 % | ||||
| Number Of Shares Shorted | 5.52 M | ||||
| Price To Earning | (1.04) X | ||||
| Price To Book | 2.80 X | ||||
| EBITDA | (134.46 M) | ||||
| Net Income | (142.19 M) | ||||
| Cash And Equivalents | 193.34 M | ||||
| Cash Per Share | 4.16 X | ||||
| Total Debt | 27.11 M | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 5.81 X | ||||
| Book Value Per Share | 3.56 X | ||||
| Cash Flow From Operations | (129.19 M) | ||||
| Short Ratio | 6.55 X | ||||
| Earnings Per Share | (2.96) X | ||||
| Price To Earnings To Growth | (0.45) X | ||||
| Target Price | 30.13 | ||||
| Number Of Employees | 70 | ||||
| Beta | 0.98 | ||||
| Market Capitalization | 1.07 B | ||||
| Total Asset | 596.27 M | ||||
| Retained Earnings | (457.43 M) | ||||
| Working Capital | 563.92 M | ||||
| Current Asset | 10.12 M | ||||
| Current Liabilities | 3.89 M | ||||
| Net Asset | 596.27 M |
About 89bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze 89bio Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 89bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 89bio Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether 89bio Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of 89bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of 89bio Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on 89bio Inc Stock:Check out 89bio Piotroski F Score and 89bio Altman Z Score analysis. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 89bio. If investors know 89bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 89bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Return On Assets (0.41) | Return On Equity (0.73) |
The market value of 89bio Inc is measured differently than its book value, which is the value of 89bio that is recorded on the company's balance sheet. Investors also form their own opinion of 89bio's value that differs from its market value or its book value, called intrinsic value, which is 89bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 89bio's market value can be influenced by many factors that don't directly affect 89bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 89bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if 89bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 89bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.